WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Sarah (Siedlak) Walker
Associate
Technology Transactions
San Diego
swalker@wsgr.com

D858-350-2387

Download vCard
Open PDF

Sarah (Siedlak) Walker is an associate in the technology transactions practice in Wilson Sonsini Goodrich & Rosati’s San Diego office. Her practice focuses on the life sciences and medical device industries, representing companies in various intellectual property and commercial transactions. Sarah has also represented life sciences, medical device, and software companies in patent infringement disputes, including Hatch-Waxman litigation. 

Sarah represents the San Diego office on the firm’s Associates Committee and Women of Wilson affinity group. 

During law school, Sarah interned at Case Western Reserve University School of Law's Intellectual Property Venture Clinic, where she represented start-up companies and focused on business and intellectual property matters such as drafting patent applications, forming corporate entities, and negotiating patent licenses.

Experience

Sarah (Siedlak) Walker is an associate in the technology transactions practice in Wilson Sonsini Goodrich & Rosati’s San Diego office. Her practice focuses on the life sciences and medical device industries, representing companies in various intellectual property and commercial transactions. Sarah has also represented life sciences, medical device, and software companies in patent infringement disputes, including Hatch-Waxman litigation. 

Sarah represents the San Diego office on the firm’s Associates Committee and Women of Wilson affinity group. 

During law school, Sarah interned at Case Western Reserve University School of Law's Intellectual Property Venture Clinic, where she represented start-up companies and focused on business and intellectual property matters such as drafting patent applications, forming corporate entities, and negotiating patent licenses.

Education
  • J.D., Case Western Reserve University School of Law, 2017Order of the Coif; Magna Cum Laude; Managing Editor, Case Western Reserve Law Review; Recipient, CALI Excellence for the Future Award in Contracts, Corporate Finance, Venture Finance and Transactions, LLEAP 4: Experiential Learning, and Intellectual Property Venture Clinic; Student Representative, William K. Thomas Inn of Court; Recipient, Diane Ethics Award; Recipient, Stanley I. and Hope S. Adelstein Environmental Law Award
  • B.S., Marine Science and Biology, University of Miami, 2014Minor in Chemistry
Admissions
  • State Bar of California
  • U.S. Patent and Trademark Office
Credentials
Education
  • J.D., Case Western Reserve University School of Law, 2017Order of the Coif; Magna Cum Laude; Managing Editor, Case Western Reserve Law Review; Recipient, CALI Excellence for the Future Award in Contracts, Corporate Finance, Venture Finance and Transactions, LLEAP 4: Experiential Learning, and Intellectual Property Venture Clinic; Student Representative, William K. Thomas Inn of Court; Recipient, Diane Ethics Award; Recipient, Stanley I. and Hope S. Adelstein Environmental Law Award
  • B.S., Marine Science and Biology, University of Miami, 2014Minor in Chemistry
Admissions
  • State Bar of California
  • U.S. Patent and Trademark Office

Select Publications

  • "How Can States Outside the Gulf of Mexico Regulate Offshore Finfish Aquaculture?" Case Western Reserve Law Review, Vol. 67, Issue 4, 2017
  • "Who Ya Gonna Call? Ghostbloggers!" Cleveland Metropolitan Bar Journal, July/August 2017
Insights

Select Publications

  • "How Can States Outside the Gulf of Mexico Regulate Offshore Finfish Aquaculture?" Case Western Reserve Law Review, Vol. 67, Issue 4, 2017
  • "Who Ya Gonna Call? Ghostbloggers!" Cleveland Metropolitan Bar Journal, July/August 2017
Focus Areas
  • Technology Transactions
Recent Insights
Client Highlights
Firm Advises Edgewise Therapeutics on Its Sale of Sevasemten for up to $2.65 Billion
On June 1, 2026, Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, announced that it has entered into a definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, will acquire sevasemten, an orally administered fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies, and Edgewise's muscular dystrophy business for $1.55 billion in upfront cash consideration and up to $1.1 billion in additional milestone payments, for aggregate potential consideration of up to $2.65 billion. The transaction strengthens Edgewise’s balance sheet, providing enhanced financial flexibility and sharpening the company’s strategic focus to accelerate and unlock the full potential of its cardiovascular pipeline. Wilson Sonsini Goodrich & Rosati advised Edgewise on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Omeros on Asset Purchase and License Agreement with Novo Nordisk
On October 15, 2025, Novo Nordisk and Omeros Corporation announced that they have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (OMS906) in clinical development for rare blood and kidney disorders. Wilson Sonsini Goodrich & Rosati advised Omeros on the transaction.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.